Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan 8;13(1):131.
doi: 10.3390/biomedicines13010131.

Imaging the Brainstem Raphe in Medication-Overuse Headache: Pathophysiological Insights and Implications for Personalized Care

Affiliations

Imaging the Brainstem Raphe in Medication-Overuse Headache: Pathophysiological Insights and Implications for Personalized Care

Annika Mall et al. Biomedicines. .

Abstract

Background/Objectives: Medication-overuse headache (MOH) is a disabling condition affecting patients with chronic migraine resulting from excessive use of acute headache medication. It is characterized by both pain modulation and addiction-like mechanisms involving the brainstem raphe, a region critical to serotonergic signaling. This study investigates whether alterations in the brainstem raphe, assessed via transcranial sonography (TCS), are associated with MOH and independent of depressive symptoms, aiming to explore their utility as a biomarker. Methods: This prospective case-control study included 60 migraine patients (15 with MOH) and 7 healthy controls. Comprehensive clinical and psychometric assessments were performed to evaluate headache burden, medication use, and depressive symptoms. TCS was used to assess brainstem raphe echogenicity, with findings analyzed using generalized linear models adjusted for depression. Results: Non-visibility of the brainstem raphe was significantly associated with MOH, with an unadjusted odds ratio (OR) of 6.88 (95% CI: 1.32-36.01, p = 0.02). After adjusting for depressive symptoms, this association remained significant, with an adjusted OR of 1.85 (95% CI: 1.02-3.34, p = 0.041). TCS demonstrated good intraclass correlation, highlighting its reproducibility and ability to detect changes relevant to MOH pathophysiology. Conclusions: Brainstem raphe alterations are associated with MOH and may serve as a potential biomarker for its diagnosis and management. TCS offers a non-invasive, cost-effective tool for identifying MOH-specific mechanisms, which could improve clinical decision-making and support personalized care in chronic headache disorders. Further studies are needed to validate these findings and refine the clinical applications of brainstem-focused diagnostics.

Keywords: addiction; biomarker; brainstem raphe; chronic migraine; medication-overuse headache; migraine; precision medicine; serotonergic system; transcranial ultrasound.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Illustration of TCS findings in comparison to MOH probability in the study sample. While any visibility of the brainstem raphe (i.e., continuous or discontinuous) was associated with rather low probabilities of MOH, an invisible brainstem raphe increased the odds of suffering MOH. Grey dashed lines indicate the visibility category to which the respective figure belongs. Solid lines represent the standard deviations of the intervals of the mean probability. * = statistically different from continuous raphe.

References

    1. Rizzoli P. Medication-Overuse Headache. Continuum. 2024;30:379–390. doi: 10.1212/CON.0000000000001403. - DOI - PubMed
    1. Lipton R.B., Fanning K.M., Buse D.C., Martin V.T., Hohaia L.B., Adams A.M., Reed M.L., Goadsby P.J. Migraine progression in subgroups of migraine based on comorbidities: Results of the CaMEO Study. Neurology. 2019;93:e2224–e2236. doi: 10.1212/WNL.0000000000008589. - DOI - PMC - PubMed
    1. Olesen J. International Classification of Headache Disorders. Lancet Neurol. 2018;17:396–397. doi: 10.1016/S1474-4422(18)30085-1. - DOI - PubMed
    1. Diener H.C., Holle D., Solbach K., Gaul C. Medication-overuse headache: Risk factors, pathophysiology and management. Nat. Rev. Neurol. 2016;12:575–583. doi: 10.1038/nrneurol.2016.124. - DOI - PubMed
    1. Carlsen L.N., Rouw C., Westergaard M.L., Nielsen M., Munksgaard S.B., Bendtsen L., Jensen R.H. Treatment of medication overuse headache: Effect and predictors after 1 year-A randomized controlled trial. Headache. 2021;61:1112–1122. doi: 10.1111/head.14177. - DOI - PubMed

LinkOut - more resources